120 related articles for article (PubMed ID: 38657828)
1. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain.
Kim E; Frouni I; Shaqfah J; Bédard D; Huot P
J Chem Neuroanat; 2024 Jul; 138():102422. PubMed ID: 38657828
[TBL] [Abstract][Full Text] [Related]
2. [
Frouni I; Kim E; Shaqfah J; Bédard D; Kwan C; Belliveau S; Huot P
Exp Brain Res; 2024 May; 242(5):1203-1214. PubMed ID: 38526743
[TBL] [Abstract][Full Text] [Related]
3. The highly selective mGlu
Hamadjida A; Sid-Otmane L; Kwan C; Frouni I; Nafade V; Bédard D; Gagnon D; Wallman MJ; Rouillard C; Parent A; Parent M; Huot P
Eur J Neurosci; 2020 Jun; 51(12):2412-2422. PubMed ID: 31944461
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic labelling of 5-HT
Kwan C; Lévesque C; Bédard D; Frouni I; Yesuf JM; Hamadjida A; Lévesque D; Clarke PB; Huot P
Neurosci Res; 2022 Apr; 177():135-144. PubMed ID: 34954302
[TBL] [Abstract][Full Text] [Related]
5. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Aristieta A; Ruiz-Ortega JA; Morera-Herreras T; Miguelez C; Ugedo L
Exp Neurol; 2019 Dec; 322():113036. PubMed ID: 31425688
[TBL] [Abstract][Full Text] [Related]
6. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
7. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
8. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
[TBL] [Abstract][Full Text] [Related]
9. Combined 5-HT
Kwan C; Frouni I; Nuara SG; Belliveau S; Kang W; Hamadjida A; Bédard D; Beaudry F; Panisset M; Gourdon JC; Huot P
Neuropharmacology; 2021 Mar; 186():108465. PubMed ID: 33485945
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Winkler C; Kirik D; Björklund A; Cenci MA
Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
[TBL] [Abstract][Full Text] [Related]
11. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
[TBL] [Abstract][Full Text] [Related]
12. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Johansson PA; Andersson M; Andersson KE; Cenci MA
Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
[TBL] [Abstract][Full Text] [Related]
13. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
14. Activation of mGlu 2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism.
Kang W; Frouni I; Kwan C; Desbiens L; Hamadjida A; Huot P
Behav Pharmacol; 2024 Jun; 35(4):185-192. PubMed ID: 38563661
[TBL] [Abstract][Full Text] [Related]
15. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
16. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
[TBL] [Abstract][Full Text] [Related]
17. Activation of mGlu
Frouni I; Hamadjida A; Kwan C; Bédard D; Nafade V; Gaudette F; Nuara SG; Gourdon JC; Beaudry F; Huot P
Neuropharmacology; 2019 Nov; 158():107725. PubMed ID: 31351976
[TBL] [Abstract][Full Text] [Related]
18. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
19. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
